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Milan, ItalyAbstractIn this single-centre, retrospective study, we analyzed data of 194
patients receiving antiretroviral therapy with <50 human
immunodeﬁciency virus (HIV) RNA copies/mL in plasma and 318
HIV RNA/DNA paired samples. By kinetic polymerase chain
reaction (kPCR) molecular system analysis, 104 (54%) subjects
had undetectable HIV RNA and 90 (46%) had residual viraemia.
Median (interquartile range) HIV DNA load was 780 (380–1930)
copies/106 peripheral blood lymphocytes (PBL), and HIV DNA
loads were independently associated with residual viraemia
(p 0.002). Virological rebound occurred in 29/194 (15%) patients
over a median (interquartile range) follow-up of 17.5 (13.5–31.5)
months. Residual viraemia (p 0.002), but not HIV DNA load, was
independently associated with virological rebound.
Clinical Microbiology and Infection © 2014 European Society of
Clinical Microbiology and Infectious Diseases. Published by
Elsevier Ltd. All rights reserved.
Keywords: HIV-1 DNA load, kPCR, residual viraemia, virological
failure, virological rebound
Original Submission: 27 January 2014; Revised Submission:
29 July 2014; Accepted: 2 August 2014
Editor: G. Antonelli
Article published online: 13 October 2014Corresponding author: N. Gianotti, Dipartimento di Malattie
Infettive, Istituto Scientiﬁco San Raffaele, Via Stamira d’Ancona 20,
20127 Milano, Italy
E-mail: nicola.gianotti@hsr.itClinical Microbiology and Infection © 2014 European Society of CIntroductionHigh human immunodeﬁciency virus (HIV) DNA loads have
been associated with faster clinical disease progression [1–3]
and virological failure among patients initiating combination
antiretroviral therapy (cART) [4]. Furthermore, baseline HIV
DNA load has been found to be an independent predictor of
virological rebound (VR) in patients switching from a protease
inhibitor–based to a non-nucleoside reverse transcriptase in-
hibitor–based therapy [5] or to a boosted-protease inhibitor
monotherapy [6–8]. However, none of these studies assessed
whether the HIV DNA load measured while plasma HIV RNA is
<50 copies/mL is more informative than residual viraemia (RV)
with regard to the risk of VR. RV below 50 HIV RNA copies/mL
has been associated with an increased risk of VR [9–11] and
with HIV DNA loads [12,13].
The aim of this study was to investigate whether HIV DNA
was associated with VR independently from RV in HIV-infected
patients with <50 HIV RNA copies/mL receiving cART.MethodsIn this single-centre, retrospective study, we evaluated HIV-
infected patients receiving cART who had HIV RNA of <50
copies/mL, history of virological failure, clade B HIV, HIV DNA
and HIV RNA measured on the same day.
All patients provided informed consent to the treatment of
their personal data for scientiﬁc purposes.
HIV RNA was quantiﬁed by kinetic polymerase chain reac-
tion (kPCR) molecular system analysis (Versant HIV-1 RNA
kPCR 1.0; Siemens Diagnostics), which gives three possible
outputs: a quantitative result for HIV RNA levels >37 copies/
mL; a semiquantitative result (detectable below 37 copies/mL)
when HIV RNA is detectable but not precisely quantiﬁable;
and a qualitative result (undetectable) when no signal can be
detected. For the purpose of this study, RV was deﬁned by any
HIV RNA values detectable below 50 copies/mL.
HIV DNA was ampliﬁed as described previously elsewhere
[14] and quantiﬁed by real-time PCR (ABI Prism 7900).
The detectability ratio (DR) was deﬁned as the number of
HIV RNAs values >50 copies/mL divided by the total number of
HIV RNA determinations available before the ﬁrst paired
determination of HIV RNA and HIV DNA. VR was deﬁned as
two consecutive measurements of HIV RNA >50 copies/mL.
Follow-up was deﬁned as the interval since the ﬁrst HIV
RNA/DNA determination (baseline) up to the last available visit
(between January 2009 and January 2012) or the date ofClin Microbiol Infect 2015; 21: 103.e7–103.e10
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was modiﬁed for any reason.
Results are reported as median (interquartile range, IQR) or
frequency (%), as appropriate.
In the analyses considering one observation per individual,
the ﬁrst determination of HIV RNA/DNA was used.
Comparisons were performed using the Wilcoxon rank-
sum test or the chi-square/Fisher’s exact test, as appro-
priate. Linear correlation was assessed by the Spearman rank
coefﬁcient. The multivariate mixed linear model was applied
to evaluate predictors of HIV DNA values; the model
included ﬁxed variables (age, HIV risk factor, cART duration,
type of antiretroviral regimen, previous AIDS diagnosis,
nadir CD4+, DR, triple-class resistance) and current HIV
RNA as a time-varying variable; β-coefﬁcient or adjusted
mean ± standard error are reported, as appropriate. Kaplan-
Meier curves estimated the time to VR and were compared
by the log-rank test. Multivariate Cox proportional hazard
model was used to evaluate factors independently associatedTABLE 1. Demographic and clinical characteristics at the time of
study subjects
Characteristic
Overall
(n [ 194)
Male sex 156 (80%)
Age (y) 47 (43–54)
Time since ﬁrst HIV-positive test (y) 17.1 (12.1–21.5)
Previous AIDS diagnosis 46 (24%)
HCV infection
Yes 34 (18%)
No 140 (72%)
Unknown 20 (10%)
HBV infection
Yes 25 (13%)
No 145 (75%)
Unknown 24 (12%)
HIV risk factor
IDU 33 (17%)
MSM 74 (38%)
Heterosexual 33 (17%)
Other/unknown 54 (28%)
Nadir CD4+ count (cells/μL) 164 (57–264)
CD4+ count (cells/μL) 489 (357–640)
Detectability ratio 0.63 (0.45–0.79)
Duration of the antiretroviral treatment (y) 13.5 (6.7–16.3)
Type of antiretroviral treatment
NRTI-based regimen 6 (3%)
NNRTI-based regimen 12 (6%)
PI-based regimen 81 (42%)
New-drug-based regimena 95 (49%)
Most frequently used antiretroviral regimensb
Maraviroc + raltegravir + etravirine 26 (13%)
Atazanavir/r + tenofovir + emtricitabine 19 (10%)
Darunavir/r + tenofovir + emtricitabine 15 (8%)
Darunavir/r + raltegravir + etravirine 13 (7%)
At least one drug-resistance mutation for:
NRTIs 135 (73%)
NNRTIs 90 (49%)
PIs 98 (53%)
NRTIs and NNRTIs and PIs 60 (32%)
Data are expressed as n (%) or median (interquartile range).
HIV, human immunodeﬁciency virus; NRTIs, nucleoside reverse transcriptase inhibitors; NN
injection drug user; MSM, men who have sex with men.
aNew-drug-based regimens included at least one of the following drugs: maraviroc, raltegrav
bAntiretroviral regimens used in at least 5% of the considered patients.
Clinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Infectwith the risk of VR. All of the statistical tests were two sided
at the 5% level and were performed by SAS software, release
9.2 (SAS Institute).ResultsWe analyzed 194 patients with a total of 318 HIV RNA/DNA
paired samples over a median (IQR) follow-up of 17.5
(13.5–31.5) months; 134 (69%) and 33 (17%) patients had one
or two viral load paired tests; the remaining 27 (14%) patients
had at least 3 paired determinations. Demographic and clinical
characteristics are shown in Table 1.
At ﬁrst paired sample, 104 (54%) subjects had undetectable
viraemia (UV) and 90 (46%) had RV; HIV DNA load was 780
(380–1930) copies/106 PBL. Subjects with UV had lower values
of HIV DNA than subjects with RV (UV: 640 (280–1200) HIV
DNA copies/106 PBL; RV: 1090 (530–3200) HIV DNA copies/
106 PBL; p 0.001).ﬁrst paired determination of HIV RNA and HIV DNA among
Undetectable viraemia Residual viraemia
p(n [ 104) (n [ 90)
77 (74%) 79 (88%) 0.019
47 (43–52) 47 (43–55) 0.781
17.6 (11.8–22.3 17.0 (12.5–20.1) 0.289
23 (22%) 23 (26%) 0.614
0.707
19 (18%) 15 (17%)
76 (73%) 64 (71%)
9 (9%) 11 (12%)
0.455
14 (13%) 11 (12%)
80 (77%) 65 (72%)
10 (10%) 14 (16%)
0.700
21 (20%) 12 (13%)
38 (37%) 36 (41%)
16 (15%) 17 (19%)
29 (28%) 25 (27%)
149 (50–277) 166 (71–260) 0.581
502 (362–742) 479 (356–624) 0.461
0.61 (0.43–0.76) 0.67 (0.50–0.82) 0.036
13.7 (8.6–16.3) 13.5 (6.1–16.8) 0.596
0.478
4 (4%) 2 (2%)
9 (9%) 3 (3%)
43 (41%) 38 (43%)
49 (47%) 46 (52%)
0.953
12 (12%) 14 (16%)
9 (9%) 10 (11%)
8 (8%) 7 (8%)
7 (7%) 6 (7%)
75 (74%) 60 (71%) 0.740
52 (52%) 38 (45%) 0.461
54 (53%) 44 (52%) 0.999
35 (35%) 25 (30%) 0.530
RTIs, non-nucleoside reverse transcriptase inhibitors; PIs, protease inhibitors; IDU,
ir or enfuvirtide.
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pendently associated with age (−115 ± 55 copies/106 PBL per
year older, p 0.039), HIV risk factor (injection drug user:
539 ± 1501 copies/106 PBL; men who have sex with men:
3973 ± 1165 copies/106 PBL; heterosexual: 2626 ± 1543
copies/106 PBL; other/unknown: 1696 ± 1308 copies/106 PBL; p
0.041), DR (680 ± 248 copies/106 PBL per 10% higher, p 0.007)
and current HIV RNA (UV: 817 ± 1156 copies/106 PBL; RV:
3601 ± 1215 copies/106 PBL; p 0.002).
VR occurred in 29/194 (15%) subjects during follow-up; viral
load at failure was 167 (81–1932) HIV RNA copies/mL. Patients
with RV had higher probability of VR than those with UV
(Fig. 1b, p 0.006), whereas higher HIV DNA loads were not
associated with a higher probability of VR (Fig. 1c, p 0.714).
At multivariate analysis, only nadir CD4+ count (AHR per
100 cells/μL higher = 0.605; 95% conﬁdence interval
0.391–0.937; p 0.049), DR (AHR per 10% higher = 1.464; 95%
conﬁdence interval 1.093–2.078; p 0.019) and current HIV
RNA (AHR (UV vs RV) = 0.163; 95% conﬁdence interval
0.051–0.527; p 0.002) were independently associated with VR.DiscussionFIG. 1. (a) Kaplan-Meier curves of the time to virological rebound (VR)
since baseline (overall). (b) Kaplan-Meier curves of the time to VR since
baseline in patients with or without residual viraemia. (c) Kaplan-Meier
curves of the time to VR since baseline in patients with human immu-
nodeﬁciency virus DNA above or below the observed median value.Our study conﬁrms that RV is independently associated with
VR during follow-up in patients attaining <50 HIV RNA copies/
mL [9–11]. However, we did not ﬁnd an association between
HIV DNA loads and VR during follow-up; this seems in contrast
with previous studies [4,5,8] where the analyses could not be
adjusted for the effect of RV. According to our ﬁndings, an
ultrasensitive method (such as kPCR) to quantify RV in patients
who attained <50 HIV RNA copies/mL in plasma appears more
reliable than quantiﬁcation of HIV DNA in predicting VR during
follow-up; we can also hypothesise that RV could be a more
sensitive predictor of ongoing viral replication compared to
total HIV DNA quantiﬁcation. Indeed, the majority of proviral
HIV-1 genomes present in the cell reservoirs were shown to be
defective or will unlikely become replicating viruses [15–17].
Our study conﬁrms in a larger data set the ﬁndings of smaller
one [18] and expands knowledge by investigating the role of RV.
Limitations of our study include its retrospective design and
the relatively small sample size, although this sample was large
enough to detect and independent association between RV and
VR. Thus, we are conﬁdent about the pre-eminent effect of RV,
with respect to HIV DNA load, on VR in these patients.
In conclusion, in HIV-infected patients with <50 HIV RNA
copies/mL, HIV DNA load was independently and directly
associated with RV, but VR was not independently associated
with HIV DNA loads. Under a clinical perspective, the quanti-
ﬁcation of HIV DNA appears to be less useful than anClinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Infultrasensitive method (such as kPCR) to quantify HIV RNA to
monitor these patients.
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